MALARIA (PLASMODIUM FALCIPARUM)
Clinical trials for MALARIA (PLASMODIUM FALCIPARUM) explained in plain language.
Never miss a new study
Get alerted when new MALARIA (PLASMODIUM FALCIPARUM) trials appear
Sign up with your email to follow new studies for MALARIA (PLASMODIUM FALCIPARUM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New malaria vaccine shows promise in african trial
⭐️ VACCINE ⭐️ Recruiting nowThis study tests a new malaria vaccine in 180 healthy adults aged 18-50 in Burkina Faso. The vaccine uses weakened malaria parasites that stop growing in the liver, so they cannot cause blood-stage infection. Participants receive either one or two doses of the vaccine or a placeb…
Matched conditions: MALARIA (PLASMODIUM FALCIPARUM)
Phase: PHASE2 • Sponsor: Sanaria Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 13:01 UTC
-
Malaria vaccine booster trial aims to keep school kids protected
⭐️ VACCINE ⭐️ Recruiting nowThis study tests a booster shot of the R21/Matrix-M malaria vaccine in 40 school-age children in Burkina Faso who already received four doses years earlier. Half get the standard child dose, half get a higher adult dose. Researchers will check for side effects and measure antibod…
Matched conditions: MALARIA (PLASMODIUM FALCIPARUM)
Phase: PHASE2 • Sponsor: University of Oxford • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:08 UTC
-
Cancer drug could supercharge malaria treatment and beat resistance
Disease control Recruiting nowThis study tests whether adding imatinib, a drug currently used for cancer, to the standard malaria treatment (artemether + lumefantrine) can clear the malaria parasite faster and fight drug resistance. About 1,100 adults with mild to moderate malaria will receive either the stan…
Matched conditions: MALARIA (PLASMODIUM FALCIPARUM)
Phase: PHASE2 • Sponsor: Victoria Biomedical Research Institute • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC